Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `amp_init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `schema-and-structured-data-for-wp` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/u885321871/domains/fintechinshorts.com/public_html/wp-includes/functions.php on line 6114

Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `amp_init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `schema-and-structured-data-for-wp` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/u885321871/domains/fintechinshorts.com/public_html/wp-includes/functions.php on line 6114

Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `schema-and-structured-data-for-wp` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/u885321871/domains/fintechinshorts.com/public_html/wp-includes/functions.php on line 6114

Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `schema-and-structured-data-for-wp` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/u885321871/domains/fintechinshorts.com/public_html/wp-includes/functions.php on line 6114
Invex Therapeutics: Receives green light for IIH trial in NZ | Fintech InShorts: Latest fintech news, analysis by experts

Less than 1 min.Read

Invex Therapeutics: Receives green light for IIH trial in NZ

By Steve Sam

November 25, 2022

Invex Therapeutics Receives green light for IIH trial in NZ

Invex Therapeutics (IXC) will commence its IIH EVOLVE Phase III clinical trial after receiving the relevant approvals
The company got the green light by the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) as well as ethics approval to start the trial
The EVOLVE trial will include 240 patients with idiopathic intracranial hypertension to determine the efficacy and safety of Presendin versus placebo over six months
The primary endpoint of the trial is to see a change in intracranial pressure as measured by lumbar puncture, both at baseline and at the end of the trial
Shares in Invex are down 9.24 per cent, trading at 54 cents at market close.

Tags
Invex Therapeutics

Hot this week

Topics

Popular Categories

FinTechBankingBusinessFundingAIPaymentsPartnership

Propel Holdings: Moves into Canada

SaaScada & Times International: Partner to deliver innovative trade and commerce financial solutions

Invex Therapeutics: Receives green light for IIH trial in NZ

Invex Therapeutics Receives green light for IIH trial in NZ

Banking as a Service: Meaning, Examples, Benefits and Future

Best fintech blogs and websites

What is Fintech?

How to buy shares online

Is it worth investing in life insurance over 60?

Topics

Singapore-based fintech start-up WSPN bags $30m seed funding

Mastercard set to lay off around 3% of global workforce

HSBC reportedly considering sale of its South African business

ABN Amro goes live with CBA’s IBAS TDD software and nCino’s cloud banking platform

USAA president and CEO Wayne Peacock to retire in 2025

Singapore’s Valverde taps Broadridge for investment management solution

US fintech Amount lands $30m in fresh funding to advance AI capabilities

Sharon Naidoo named new TransUnion CFO for the UK and Europe

Related Articles

Singapore-based fintech start-up WSPN bags $30m seed funding

Mastercard set to lay off around 3% of global workforce

HSBC reportedly considering sale of its South African business

ABN Amro goes live with CBA’s IBAS TDD software and nCino’s cloud banking platform

USAA president and CEO Wayne Peacock to retire in 2025

Company

Headlines

Singapore-based fintech start-up WSPN bags $30m seed funding

Mastercard set to lay off around 3% of global workforce

HSBC reportedly considering sale of its South African business

ABN Amro goes live with CBA’s IBAS TDD software and nCino’s cloud banking platform

Newsletter